The CD62L+ subpopulation of Tregs has been shown to possess more potent suppressive and proliferative capacity in vitro than the CD62L− (66) and only CD62L+ Tregs delayed the development of diabetes in an adoptive transfer model (67) and protected mice from acute GVHD (68). Here, SELL is linked to graft versus host disease.